New therapy for pimples
According to a research reported in the British Journal of Dermatology, a blue and red light mixture seems to be most effective treatment for acne - reducing the number of spots by three-quarters.As many as one in 18 adults have persistent
pimples, which can prove stubbornly resistant to both creams and antibiotics. Some acne does clear up significantly when exposed to UV light. Th...
Rapimal MT Pf Dipstick
Description:The Cellabs Ra
pimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by at the merozoite (red blood cell) stage of the infection....
Company:Cellabs
Allergens, Food, Pimento
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Allergens, Food, Pimiento
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
Clinical Benefit Shown in 35% of HER2-Positive Metastatic BreastCancer Patients HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a Phase 1 clinicaltrial showing that alves
pimycin, its second-generation Hsp90inhibitor, demonstrated promising antitumor activity andtolerability in combination with trastuzumab (Herceptin(R)) inpatient...
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Tanes
pimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor, tanes
pimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that tanes
pimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR
Tanes
pimycin Shown to Have No Effect on QTc Interval HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- KosanBiosciences Incorporated today presented safety data frompreclinical and clinical studies of its lead Hsp90 inhibitor,tanes
pimycin (KOS-953). Serial electrocardiogram (ECG) monitoringof patients was conducted in four Phase 1 trials of tanes
pimycin.Cardiac monitoring analyses were cond...